After nearly two decades of legal battles and negotiations, South Africa is moving to cut the cost of medicines with policies to increase imports and local production of generic drugs.
Academic rigor, journalistic flair
Articles on TRIPS
Displaying all articles
There is a window of opportunity for the least developed countries to develop their own pharmaceuticals industry.
Seven rounds of negotiations for the Regional Comprehensive Economic Partnership have already taken place with virtually no public debate. The next round of negotiations begins today in Kyoto, Japan.
India is the global focal point for legal and political struggles over patent rights and access to medicines. Particular attention is focused on the Swiss pharmaceutical giant Novartis, which is in battle…
Two large multinational pharmaceutical companies are fighting for patents and monopoly pricing in Indian courts. The outcomes of the cases – involving Novartis and Bayer – are likely to determine the country’s…
The Anti-Counterfeiting Trade Agreement (ACTA) 2011 - Twitter hashtag #ACTA - is a controversial trade agreement designed to provide for stronger enforcement of intellectual property rights. There’s been…
Top contributors
-
Associate Professor Politics and Policy Studies, Deakin University
-
Senior Lecturer in Public Health, La Trobe University
-
Professor in Intellectual Property and Innovation Law, Queensland University of Technology
-
Senior Lecturer in Law, City, University of London
-
Research Fellow, NHMRC Centre for Research Excellence in the Social Determinants of Health Equity, School of Regulation and Global Governance, Australian National University
-
Adjunct professor, Department of Health Policy & Management, George Washington University
-
Associate Professor and Course Leader: Post Graduate Programmes in Clinical Pharmacy in the Department of Pharmacy, Sefako Makgatho Health Sciences University
